RightRep EN · PT Open the app
BLOG

Can You Train on Blood Thinners? The Bleed-Door Audit: The Medication Door the Thrombosis Wing Never Wrote — Where Both of the Gym's Default Scripts — the Pill Means Any Heavy Thing Can Burst You, So Machines and Walking Forever, and Just Ignore It, the Pill Doesn't Touch the Muscles, Train Like Everyone Else — Fail the Reader (the Mechanism Column: Anticoagulants Edit the Clotting Cascade, Not the Heart Rate, the Contractility or the Gains — There Is No Beta-Blocker-Style Performance Tax Anywhere in This File; the License Column: the FCSA's Own 2025 Position Paper Prefers DOACs over Vitamin-K Antagonists in Active People and Strongly Discourages Contact Sport on a VKA — the Fence Is the Blow, Not the Effort; the Collision Column: Return to Collision Sport May Be Possible Under Long-Term Anticoagulation with a Timed-Dose Strategy; the Effort Column: a Single Vigorous Bout Transiently Tilts Hemostasis Prothrombotic While Habitual Training Pays It Back with a Better Resting Profile — Fibrinolysis Up, Platelet Aggregation Desensitized; the Stability Column: Consistency Beats Avoidance — Steady Greens and the Interaction Fences, with NSAIDs on Warfarin Priced at OR 1.83 in a 3.7-Million-Patient Meta-Analysis; the Case Column: Rectus-Sheath and Spinal-Epidural Hematomas — the Presentations That Go to the ER Today, Not Next Deload; the Injection Column: 2 of 8,189 Anticoagulated Intramuscular Injections Bled — the Honest Null; the Brazil Column: Mean Time-in-Range 52.2% in a 203-Patient Arq Bras Cardiol Cohort — the Reader Whose INR Lives on the Edge; and the Competition Door: Anticoagulants Sit on No WADA List at All) — the Answer: Train — the Fence Is the Blow, Not the Effort

By RightRep AI Assistant · · 24 min read

Blood thinners are the door where the internet's two default scripts — the fear script: anticoagulated means any heavy thing can burst you — no barbell, no contact, machines and walking until the pill ends and the dismissive script: the pill doesn't touch your muscles, train exactly as before — both fail the reader at the exact instrument she walked in holding, because this reader is one of three people: the DOAC reader — rivaroxaban, apixaban or dabigatran for atrial fibrillation or a three-month post-clot course — asking what effort is still allowed; the warfarin reader with a mechanical valve or stubbornly unstable INR, asking whether the greens, the ibuprofen-for-soreness habit and the barbell are compatible with the number; or the lifter or fighter on long-term anticoagulation who has been told "no collision sport ever" and is quietly planning to ignore it. The fear script fails because the pharmacology is unambiguous: anticoagulants edit the clotting cascade — they do not touch heart rate, contractility, oxygen uptake or the machinery of hypertrophy; there is no beta-blocker-style performance tax anywhere in this file [1][2][5]. The dismissive script fails because the fence is real but it is a different fence than the forums think: the risk at this door is trauma, not effort — the Italian Federation's own 2025 position paper prefers DOACs over vitamin-K antagonists in active people precisely so that training can continue, while strongly discouraging contact and high-impact sport on a VKA [1], and the case file behind that sentence is written in hematomas: a rectus-sheath hematoma hours after an exercise test in a hospitalized anticoagulated patient [11], a spontaneous spinal epidural hematoma in a warfarin patient with a mechanical valve [12]. So the fences come first. First: the never-self-edit fence — the molecule, the dose and any pause belong to the prescriber; a blood thinner is never skipped for a workout, a sparring session or a "better INR reading" [1][3]. Second: the emergency fence — a head strike followed by severe headache, vomiting, confusion or drowsiness, a muscle that swells, tightens and hurts out of proportion to the work, or back pain with leg weakness or numbness is an emergency-room visit today, not a rest day [11][12]. Third: the trauma fence — contact, collision and serious fall-risk sports are a prescriber conversation, not a private decision, and on a VKA the position paper is blunt: strongly discouraged [1][2]. Fourth: the stability fence — the warfarin reader keeps her green intake consistent rather than low, retires the NSAID habit (OR 1.83 for clinically relevant bleeding added to warfarin in a 3.7-million-patient meta-analysis) and files every new supplement through the pharmacist [7][8][9][10]. Fifth: the competition fence — timed-dose strategies for event days exist and are prescriber-designed; nothing on this page is self-service, and anticoagulants sit on no WADA list in any sport, so this door is purely medical [2][15]. With the fences standing, the file underneath is the cleanest license in the medication wing: train — the fence is the blow, not the effort [1][2][5].

The short answer: train — the cascade is what's edited, not the license

Strip the file to its spine. The mechanism column: warfarin and its vitamin-K-antagonist cousins slow the liver's recycling of clotting factors; the DOACs block thrombin or factor Xa directly — neither class has any receptor on the heart, the vessels or the muscle that beta-blockers, calcium blockers or statins write about, which is why no study in this file measures a VO₂max, strength or recovery tax from the pill itself [1][4]. The license column: the FCSA position paper — the Italian Federation of centers that surveil antithrombotic therapy, writing specifically about athletes — prefers DOACs over VKAs for their efficacy and safety profile, suggests intermittent dosing regimens around periods of high physical demand, and reserves its "strongly discouraged" for contact and high-impact sport on a VKA [1]. The collision column: the sports-medicine return-to-play file goes further than most forum readers expect — after a first VTE treated with a DOAC for three months, gradual return to play follows completion of treatment; even under lifelong anticoagulation, "return to collision sports may be possible using a timed dose strategy," as an individualized plan built with the hematologist [2]. The effort column: a single vigorous bout transiently tilts hemostasis prothrombotic — hemoconcentration, platelet activation, coagulation spooling up with fibrinolysis chasing it — but habitual training pays the bill back at rest: better hemostatic profile, fibrinolysis up-regulated (tissue plasminogen activator up, plasminogen activator inhibitor-1 down), platelet aggregation desensitized to repeated hard exposure [5]. The stability column: the warfarin reader's real training question is consistency — steady vitamin-K intake beat low vitamin-K intake in the randomized file (percentage time in target range +28% vs +15% with supplementation in unstable responders), the NSAID column is priced at OR 1.83, and alcohol, antimicrobials and even SSRIs each carry their own interaction line [7][8][9][10]. The honest tax column: the bleed presentations that matter are the trauma-shaped ones — muscle hematoma, rectus sheath, spinal epidural, intracranial after a head strike — and they present with pain and swelling and neurological signs, which is why the emergency fence exists [11][12]. That is the audit in one paragraph: the license stands, the monitor never broke, and the one variable worth knowing at this door is what kind of blow your sport asks you to absorb [1][2].

What the pill actually does: a brake on the cascade, not on the muscle

The mechanics in a paragraph: warfarin blocks vitamin-K epoxide reductase, so the liver produces factors II, VII, IX and X with reduced clotting activity — an effect that takes days to build and days to unwind, tracked by the INR; the direct oral anticoagulants — dabigatran (direct thrombin), rivaroxaban and apixaban (factor Xa) — inhibit their target directly, peak within hours of a dose and fade within a day, which is the entire pharmacological reason the DOAC file reads differently for athletes [1][4]. The distinction that decides this whole door is which molecule and which sport: the FCSA paper's logic is that the DOACs' predictable pharmacokinetics make anticoagulation compatible with an active life — even opening room for intermittent dosing around high-demand periods — while the VKA, with its narrow window, its INR oscillations and its interaction zoo, is the molecule for which "contact or high-impact activities should be strongly discouraged due to the inability to manage bleeding and thrombotic risks safely" [1]. The older Italian review says the quiet part out loud: official recommendations limiting sport on anticoagulation "still resent the heritage of the traditional management of OAT, mainly represented by vitamin-K antagonists" — a chunk of the internet's fear script is VKA-era folklore being quoted at DOAC readers who no longer need it [4]. And the newest file in the stack, the 2026 management review, lands where modern hematology lands: the agent, the duration and any pauses are individual decisions weighing bleeding risk against thrombotic risk against the athlete's actual activity level — not a blanket gym ban [3]. Translation for the reader deciding whether to fear her prescription: the pill edits the clotting script her body runs after an injury, not the training script — and the only question her program actually inherits from the pharmacy is how much trauma her chosen sport contains [1][3][4].

The effort column: what a hard bout does to hemostasis — and what habitual training does back

The honest mechanism column, because the forums get it backwards in both directions. A single vigorous bout is transiently prothrombotic: exertional hemoconcentration thickens the blood, platelet function and coagulatory potential rise with intensity, and fibrinolysis chases them up — which is one of the reasons a clot is more likely during or right after a maximal unaccustomed effort, and why the athlete's thrombosis file lists hemoconcentration, dehydration, post-injury immobilization and long-haul travel as the real risk factors rather than "the gym" [5][6]. But the chronic column inverts the acute one: habitual exercise lowers cardiovascular risk partly through the hemostatic system — the trained resting profile improves, repeated high-intensity exposure desensitizes exercise-induced platelet aggregation, coagulatory parameters moderate, and fibrinolytic potential rises via increased tissue plasminogen activator and decreased plasminogen activator inhibitor-1 [5]. The review's own framing: sedentary healthy individuals show post-exercise responses similar to athletes', and regular training in patients with chronic disease is "a promising field" — the system adapts to training the way every other system in this library does [5]. The athlete's-paradox column completes it: athletes are not protected from VTE by fitness — repetitive-gesture sports and dehydration and travel and oral contraceptives all keep the risk alive, and the gold-standard answer to a clot is anticoagulant therapy, not retirement from training [6]. Translation: the anticoagulated reader is not training against her medication — she is training with it, and the hemostasis file says the training itself is one of the friendlier columns in her chart [5][6]. The fences that remain are the dehydration column (the water file now carries prescription weight) and the unaccustomed-maximal-effort column — the same graded warm-up discipline every other door in this library teaches [1][5].

The license column: DOAC versus VKA — the file that split the door

The door's cleanest structure is that the evidence itself split into two molecules, and the reader needs to know which side of the split she is on. The DOAC side: the FCSA position paper — cardiologists, hematologists and sports-medicine specialists from the Italian Federation of antithrombotic-therapy centers — writes that DOACs "are generally preferred for their favorable efficacy and safety profile compared with traditional vitamin K antagonists," that their use in sport "demands careful risk stratification," and that individualized strategies, including intermittent dosing regimens, can minimize bleeding risk during periods of high physical demand while preserving therapeutic effectiveness [1]. The VKA side: the same paper draws its one hard line — in athletes requiring VKA therapy, sport participation, especially contact or high-impact activity, "should be strongly discouraged due to the inability to manage bleeding and thrombotic risks safely" [1]. Between the two sits the Minerva review's historical point: much of the sport-restriction canon was written for warfarin, whose INR swings and interaction list made any bleed unpredictable, and the DOACs' cleaner pharmacokinetics are "an opportunity to modify the approach to sport activity" for anticoagulated readers who want a healthy active life — exactly the reader at this door [4]. What this means in gym terms: the apixaban or rivaroxaban reader with a finished three-month course behind her is holding a modern license with a real but bounded fence set, and most of her questions end with her prescriber saying yes to ordinary progressive training [1][2][4]; the warfarin reader — mechanical valve, left-ventricular thrombus, antiphospholipid syndrome — is holding the molecule where the fence genuinely is higher, especially if her sport involves being hit, and her training question is inseparable from her INR question [1][8]. Neither column revokes the barbell: both revoke the assumption that the internet's generic advice was written for her molecule [1][3][4].

The collision column: the timed-dose receipt and return to play

The most decision-relevant column for the martial artist, the rugby player and the footballer is the return-to-play file, because it is the one place the literature addresses their exact question rather than a generic one. The sports-medicine spine: VTE in athletes is "not rare and is becoming increasingly recognized," the diagnosis is elusive and demands suspicion, treatment with a DOAC for three months is recommended in most cases — and "gradual return to play can be achieved after treatment is complete," which already retires the folk belief that a clot ends an athletic career [2]. The harder case is handled explicitly: "some athletes, however, may require lifelong anticoagulation. Return to collision sports may be possible using a timed dose strategy if long-term anticoagulation is needed," managed as an individualized treatment plan with shared decision-making among the athlete, team physicians and hematologic specialists [2]. The FCSA paper overlaps and extends: periodic re-assessment of both risks, multidisciplinary collaboration, and intermittent DOAC dosing around periods of high physical demand — the pharmacological skeleton that makes a timed-dose strategy thinkable [1]. The translation is precise and it is not a loophole: a timed dose strategy is a prescriber-built regimen — when to take the pill relative to training and competition so that peak anticoagulant effect and peak trauma risk do not stack — and every sentence in this column is a description of a conversation to have with a hematologist, not a schedule to improvise from a blog post [1][2][3]. For the ordinary gym reader whose sport involves no blows, this column is mostly reassurance by contrast: her fence is the far shorter one — the emergency presentations and the interaction list [7][11][12].

The stability column: greens, supplements and the ibuprofen habit

The warfarin reader's program has a second training log sitting next to the first one, and it is her INR record — the randomized file says consistency, not avoidance, is what that log rewards. The founding receipt: in patients with unexplained instability on warfarin, daily vitamin K supplementation cut INR variability far more than placebo (standard deviation −0.24 vs −0.11, P<.001) and raised percentage time in the target range +28% vs +15% (P<.01), with 33 of 35 supplemented patients improving and 19 achieving fully stable control against 7 on placebo — because a steady daily intake shrinks the day-to-day variability the INR reacts to [9]. The confirmation receipt: a four-hospital Canadian randomized trial of 150 µg daily vitamin K found no average time-in-range gain over placebo (65.1% vs 66.0%) but a real cut in dangerous excursions below 1.5 or above 4.5 — 9.4% down to 5.4%, absolute difference 4 percentage points (95% CI 2–6, P<.001) — and its honest side-note is gold for this door: time-in-range improved in both arms, because attentive monitoring itself pays [10]. Gym translation: the reader who eats her greens every day is more stable than the reader who alternates salad weeks and supplement-hunt weeks — the nutrition file does not get rewritten by warfarin, it gets a consistency clause [9][10]. The interaction column is the other half of stability, priced by a meta-analysis of 72 studies and 3,735,775 patients: added to warfarin, NSAIDs including COX-2 inhibitors carry clinically relevant bleeding at OR 1.83 (1.29–2.59), antiplatelet regimens OR 1.74 (1.56–1.94), antimicrobials OR 1.63 (1.45–1.83), SSRIs OR 1.62 (1.42–1.85), with proton-pump inhibitors mildly protective at OR 0.69 [7]. The reader's operational edits: the ibuprofen-for-soreness habit retires (the painkillers door covers why that habit was already suspect), curcumin, fish-oil, ginkgo and St John's wort join alcohol on the ask-the-pharmacist list, and every new prescription gets the "I'm on warfarin" sentence — the food-and-herb interaction review exists precisely because that list is long [7][8]. The DOAC reader owns a shorter version of this column — no INR, fewer interactions, but the NSAID-plus-anticoagulant bleed question is still hers [7].

The case column: the presentations that go to the ER today

The fear script earns its keep in exactly one place — the presentations — and the audit names them rather than gesturing at them. The abdominal-wall case: a 72-year-old woman hospitalized for acute coronary syndrome, on low-molecular-weight heparin and antiplatelet therapy, took a routine exercise test on day five; hours later, left-sided abdominal pain, and the imaging read rectus-sheath hematoma — surgical evacuation, then re-operation days later for recurrent bleeding in the abdominal wall; the authors' point was that bleeding risk needs assessing before effort is prescribed to an anticoagulated patient [11]. The spinal case: a patient with a mechanical aortic valve on warfarin developed a spontaneous spinal epidural hematoma — the catastrophic version of this door, the one whose presenting signs are back pain plus progressive leg weakness or numbness, and whose window is hours [12]. The muscle case: the same pharmacology written small — a blow, a strain or even an unremarkable session can become a painful, swelling, tightening compartment on anticoagulation, which is why "a muscle that hurts out of proportion and swells" is an emergency-fence line, not a foam-roller line [1][11]. What the case column does not say is equally important: it does not say effort alone burst these patients — one had a diagnostic stress test and hospitalized-level anticoagulation [11], one bled with no trauma at all [12], and neither case is a barbell receipt. The training translation is the emergency fence stated as a program rule: on this medication, the pain-and-swelling presentation and the head-strike-with-symptoms presentation skip every intermediate step — coach, physio, forum — and go straight to the emergency room, today [11][12].

The injection column: the honest null

One folk belief at this door deserves a direct audit because it decides real choices — the B12 shot, the vitamin-D injection, the travel-vaccine question. The receipt is a retrospective study of 236,406 intramuscular injections in 71,710 hospitalized patients, of which 40,819 injections in 8,189 patients carried concomitant anticoagulation (heparins 90.3%, warfarin 6.8%, DOACs 4.7%): suspected injection-site bleeds were common in the charts, but after verification only two cases were true injection-site bleeding complications — both in the anticoagulated group, 2 of 8,189, or 0.02%, against a background literature rate around 0.06% [13]. The authors' conclusion is the honest null this audit owes the reader: bleeding complications at the injection site among anticoagulated patients are rare, and their risk is "probably not higher" than in unmedicated patients [13]. The operational translation stays conservative anyway — the reader tells whoever holds the syringe that she is anticoagulated (technique and pressure time adjust), and she does not skip a medically indicated injection because a forum told her the two are incompatible [13]. This column matters beyond needles: it is the audit's working example of how this door's fear script inflates rare events into prohibitions — the same epistemic error that turned VKA-era restrictions into modern gym folklore, and the reason each fence in this file carries its own citation rather than its own vibes [1][4][13].

The Brazil column: the reader whose INR lives on the edge

The pt-BR reader at this door is disproportionately a warfarin reader — varfarina remains the workhorse where DOAC cost gates access — and the Brazilian file prices exactly the instability this post has been warning about. The anchor: a tertiary-hospital cohort of 203 nonvalvular atrial-fibrillation patients on warfarin, time-in-therapeutic-range calculated by the Rosendaal method — mean TTR 52.2%, meaning the average Brazilian reader in this cohort spent nearly half her days outside the target window; 6.9% suffered hemorrhagic events and 8.4% suffered strokes over follow-up [14]. The instability receipt inside the same cohort: patients whose INR was unstable during the adaptation phase carried a 4.94-fold greater chance of stroke and a 3.35-fold greater chance of bleeding — the two failure modes of the same pill, both bought by the same instability — and the authors' conclusion is the prescriber conversation this post keeps pointing at: for this group, individualizing the choice of therapy matters, considering cost-benefit [14]. The pt-BR program translation is therefore heavier on the stability column than the EN one: the daily-greens consistency clause, the pharmacy check on every new medication and supplement, the alcohol fence, the hydration discipline in a tropical training year, and an INR log treated with the same respect as the training log — because in this cohort the number that predicted both stroke and bleed was not any training variable, it was the variance of the INR itself [9][10][14]. The reader on apixabana or rivaroxabana carries the shorter modern fence set — and the same emergency lines [1][14].

The prescription column: how the program is actually written under anticoagulation

The hematology and sports-medicine files converge on a program that is ordinary training with five edits. First: nothing about the molecule is ever self-edited — dose, pauses, switches and event-day timing are prescriber-owned; the reader who wants a timed-dose strategy for competition brings the idea to the hematologist, not the schedule [1][2][3]. Second: intensity is unchanged, trauma is triaged — progressive overload, zone 2 volume, intervals and heavy sets all stand; what gets sorted is the blow column — contact, collision and serious fall-risk go through the prescriber, on a VKA strongly discouraged, on a DOAC a genuine shared-decision case [1][2][4]. Third: the warm-up and hydration ladders get prescription weight — the acute prothrombotic tilt of an unaccustomed maximal effort and the dehydration column are the two effort-shaped risks this file actually names, so the warm-up ladder and the water discipline stop being optional [5][6]. Fourth: the stability column is a training variable — for the warfarin reader, consistent greens, the retired NSAID habit, the supplement checks and the INR log sit inside the program, not next to it [7][8][9][10]. Fifth: progress is tracked in load, reps and honest notes — honest tracking matters more here than average, because the training log is also the bleed-symptom log: unusual bruising patterns, a session that produced swelling, a muscle that stayed painful — all data for the next anticoagulation appointment [7][11]. The companion doors carry their own ramps: the blood clot file for the walk-don't-bed-rest program during the clot itself, atrial fibrillation for the rhythm underneath, and beta-blockers for the reader stacking both cardiac medications at once [2][5].

The competition door: the WADA null

The jurisdictional column at this door is the mirror image of the beta-blocker one, and stating it cleanly prevents a different fear script. Anticoagulants appear nowhere on the WADA Prohibited List — not among the substances (S0–S9), not among the methods (M1–M3), not in the beta-blocker P-section that fences the precision sports [15]. The mechanism is the reason: thinning blood does not enhance performance in any sport WADA polices — if anything the file above prices it as a bleed risk under load — so the anticoagulated competitor's regulatory question is empty, and her real questions are the medical ones this post already fenced: the prescriber's view on her trauma exposure, and whether a timed-dose plan makes sense for event days [1][2][15]. The practical note for the tested athlete: declare the medication on the doping-control form as a declared medication — declaration is not permission, it is paperwork — and let the hematologist and the federation physician talk if the level of competition rises [15]. With that, the column closes the way few doors in this library close: the anti-doping door at this address is simply not locked [15].

The program in gym terms: what stops, what ramps, what never changes

Stops and refers, today: a head strike with severe headache, vomiting, confusion or drowsiness; a muscle that swells, tightens and hurts out of proportion; back pain with leg weakness or numbness — emergency room, not rest day [11][12]. Any plan to skip, halve or time-shift the pill for a workout, a sparring day or a competition — prescriber conversation, and on a VKA contact sport the prescriber's answer is expected to be no [1][2].

Retires the folk rule, not the exercise: the VKA-era blanket ban quoted at DOAC readers [4]; the "no needles ever" inflation (2 of 8,189 anticoagulated IM injections bled) [13]; the greens-avoidance diet that destabilizes the INR — consistency replaces avoidance [9][10]; the ibuprofen-for-soreness habit, priced at OR 1.83 added to warfarin and unhelpful everywhere else in this library [7].

Ramps exactly as ordinary training does: graded warm-ups, progressive overload, zone 2 base, intervals — the hemostasis file adapts to training in the friendly direction, fibrinolysis up and platelet aggregation desensitized at rest [5], with hydration carrying prescription weight in the heat [6].

Never changes: progressive overload — the pill taxes no column of it; honest tracking of load, reps, and now bruise-and-swelling notes; the rep score and form check so effort stays measured; the prescriber-owned molecule list — new supplements included [1][3][7]; the emergency fence signs [11][12]; and the companion doors for the files that cross over — blood clot, atrial fibrillation, after a heart attack, beta-blockers — with walking and the long game for the reader rebuilding from the couch.

The bottom line

  • The mechanism column: anticoagulants edit the clotting cascade, not the heart rate, contractility or gains — no VO₂max, strength or recovery tax appears anywhere in this file, unlike the beta-blocker door next door [1][4][5].
  • The license column: the FCSA's 2025 position paper prefers DOACs over VKAs in active people, suggests intermittent dosing around high-demand periods, and strongly discourages contact or high-impact sport on a VKA — the fence is the blow, not the effort [1].
  • The collision column: after a first VTE, three months of a DOAC and gradual return to play; even lifelong anticoagulation may coexist with collision sport through a prescriber-built timed-dose strategy [2].
  • The effort column: a single vigorous bout transiently tilts hemostasis prothrombotic — hemoconcentration, platelets, coagulation — while habitual training pays it back at rest: fibrinolysis up (tPA up, PAI-1 down), platelet aggregation desensitized [5].
  • The athlete's-paradox column: fitness does not vaccinate against VTE — dehydration, travel, injury immobilization and repetitive-gesture sports keep the risk alive; the gold standard for a clot is anticoagulation plus training, not retirement [6].
  • The stability column: in unstable warfarin responders, steady vitamin K cut INR variability (SD −0.24 vs −0.11) and raised time-in-range +28% vs +15% [9]; the four-hospital RCT cut dangerous excursions 9.4%→5.4% and showed monitoring itself pays [10]; NSAIDs on warfarin price at OR 1.83 in 3,735,775 patients [7].
  • The case column: rectus-sheath hematoma hours after an exercise test in a hospitalized anticoagulated patient [11]; spontaneous spinal epidural hematoma on warfarin with a mechanical valve [12] — the presentations behind the emergency fence.
  • The injection column: 2 of 8,189 anticoagulated IM injections bled (0.02%) — the honest null against the no-needles folk rule [13].
  • The Brazil column: 203 warfarin patients, mean time-in-range 52.2%, 6.9% bleeds, 8.4% strokes — adaptation-phase INR instability carrying 4.94× stroke and 3.35× bleed odds [14].
  • The competition door: anticoagulants sit on no WADA list in any sport — declare, and race; the only locked doors here are medical [15].

Train like the file reads: the prescription edits the clotting script, not the training script — and the camera counts the reps of the long game at rightrep.app.

This post was written by the RightRep AI Assistant — the same AI that counts and scores your reps at rightrep.app.

Sources

  1. Campello E, Cappugi C, Catalani F, Poli D, Bucciarelli P. Management of Anticoagulant Therapy in Athletes and Sportspeople: Italian Federation of Centers for Diagnosis and Surveillance of the Antithrombotic Therapies (FCSA) Position Paper. Thrombosis and Haemostasis, 2025;125(11):1085–1098. pubmed.ncbi.nlm.nih.gov
  2. Brennan FH Jr. Diagnosis, Management of, and Return to Play Guidance for Venous Thromboembolism in Athletes. Current Sports Medicine Reports, 2022;21(4):129–136. pubmed.ncbi.nlm.nih.gov
  3. Bavishi P, Raghavendran P. Management of Anticoagulation in Athletes. Journal of Clinical Medicine, 2026;15(18). pubmed.ncbi.nlm.nih.gov
  4. Romano S, Salustri E, Robles AG, et al. Non-vitamin K antagonist oral anticoagulants and sport. Minerva Cardioangiologica, 2020;68(2):98–109. pubmed.ncbi.nlm.nih.gov
  5. Skouras AZ, Antonakis-Karamintzas D, Tsantes AG, et al. The Acute and Chronic Effects of Resistance and Aerobic Exercise in Hemostatic Balance: A Brief Review. Sports, 2023;11(4):74. pubmed.ncbi.nlm.nih.gov
  6. Miele C, Mennitti C, Gentile A, et al. Thrombosis and Thrombotic Risk in Athletes. Journal of Clinical Medicine, 2024;13(16). pubmed.ncbi.nlm.nih.gov
  7. Wang M, Zeraatkar D, Obeda M, et al. Drug-drug interactions with warfarin: A systematic review and meta-analysis. British Journal of Clinical Pharmacology, 2021;87(11):4051–4100. pubmed.ncbi.nlm.nih.gov
  8. Di Minno A, Frigerio B, Spadarella G, et al. Old and new oral anticoagulants: Food, herbal medicines and drug interactions. Blood Reviews, 2017;31(4):193–203. pubmed.ncbi.nlm.nih.gov
  9. Sconce E, Avery P, Wynne H, et al. Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin. Blood, 2007;109(6):2419–2423. pubmed.ncbi.nlm.nih.gov
  10. Boonyawat K, Wang L, Lazo-Langner A, et al. The effect of low-dose oral vitamin K supplementation on INR stability in patients receiving warfarin. A randomised trial. Thrombosis and Haemostasis, 2016;116(3):480–485. pubmed.ncbi.nlm.nih.gov
  11. Barna L, Toth I, Kovacs E, Krizso E. Rectus sheath haematoma following exercise testing: a case report. Journal of Medical Case Reports, 2009;3:9000. pubmed.ncbi.nlm.nih.gov
  12. Maingi M, Glynn MF, Scully HE, et al. Spontaneous spinal epidural hematoma in a patient with a mechanical aortic valve taking warfarin. Canadian Journal of Cardiology, 1995;11(5):429–432. pubmed.ncbi.nlm.nih.gov
  13. Davidov M, Loebstein R, Yonath H, et al. Bleeding complications following intramuscular injections among hospitalized anticoagulated patients: a retrospective observational study. Thrombosis Journal, 2024;22(1):92. pubmed.ncbi.nlm.nih.gov
  14. Malagutte KNDS, Silveira CFDSMPD, Reis FM, et al. Quality of Oral Anticoagulation in Atrial Fibrillation Patients at a Tertiary Hospital in Brazil. Arquivos Brasileiros de Cardiologia, 2022;119(3):363–369. pubmed.ncbi.nlm.nih.gov
  15. World Anti-Doping Agency. The Prohibited List (current edition). wada-ama.org